Navigation Links
Osteotech Reports Fourth Quarter and Full Year 2009 Financial Results

EATONTOWN, N.J., March 4 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic products for regenerative healing, today reported financial results for the fourth quarter and full year ended December 31, 2009.  Results were in-line with the limited, preliminary financial results the Company released on January 14, 2010.

“2009 was a challenging year as we focused on launching several new, proprietary biologic products, pursuing regulatory approval for our Duratech™ BioRegeneration Matrix and making further enhancements to our distribution and sales strategy,” said Sam Owusu-Akyaw, President and Chief Executive Officer of Osteotech. “We successfully initiated the commercialization process for the MagniFuse™ Bone Graft and Plexur M® Innovative Grafting product families, and we improved the instrumentation of the FacetLinx™ Fusion Technology product.  With these significant steps forward, we continued the transformation of Osteotech to a business that is leveraging its technology assets into a portfolio of innovative and clinically efficacious procedure-specific products.”

Recent and Upcoming Corporate Developments

  • Early in the fourth quarter, the Company announced the first U.S. spinal surgery using MagniFuse PC (Posterior Cervical), which officially marked the start of the controlled release for the family of products based upon the MagniFuse technology platform.  MagniFuse PC was used during a posterior cervical fusion surgery and the surgeon cited the specialized biologic as being easy-to-use and intuitive with a differentiated self-contained delivery system. 
  • In the fourth quarter, Osteotech signed a multi-year tissue supply agreement with Community Tissue Services (CTS) with an initial term spanning 10 years. The agreement replaced a previous contract between the two companies that would have expired in 2011. Under the terms of the agreement, CTS will supply Osteotech with whole donors and cortical shafts based upon periodic forecast requirements and available tissue supply.
  • Also during the fourth quarter, the Company announced Plexur M had been utilized in a variety of surgeries focused on orthopedic trauma, joint replacements and oncology-related procedures.
  • Late in the fourth quarter, Osteotech submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) to obtain marketing clearance for the use of its Duratech BioRegeneration Matrix to repair or replace the dura mater in various cranial surgical procedures.  The Company expects to receive preliminary feedback from the FDA regarding the pending application late in the first quarter of 2010.
  • Early in the first quarter of 2010, the Company announced that it expanded its financial flexibility with a new, unused $10 million line of credit established in late December.  This new line of credit, coupled with the Company’s cash position and the consideration it will receive from a new licensing agreement, should provide the resources necessary to allow Osteotech to continue to execute its growth strategy.
  • The Company is scheduled to make a corporate presentation to investors at the Canaccord Adams Musculoskeletal Conference on March 9, 2010.
  • Osteotech intends to showcase its new proprietary biologic product portfolio at its booth (Booth No. 1061) during the Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS), in New Orleans, Louisiana from March 10 to 12, 2010.  A number of surgeons will present the clinical results stemming from their use of MagniFuse and Plexur M at the Osteotech booth during the meeting.  

“We have worked diligently to engineer products that meet the procedure-specific needs of the markets we serve, and based upon the feedback and excitement among our surgeon customers, we believe we have successfully achieved that goal,” continued Mr. Owusu-Akyaw.  “Throughout 2009, we made progress bolstering our go-to-market and distributor channel strategy, and in 2010 our goal is to significantly strengthen the selling process within the channel.  We are working toward an important inflection point where our superior products and technology and our sales strategy all converge to support long-term revenue growth and profitability.  We will continue to invest prudently in enhancing all of these essential elements of our growth strategy.”

“The new products are the key to our revenue growth in 2010 and we expect them to generate $10 million to $12 million in revenue during 2010,” continued Mr. Owusu-Akyaw.  “This assessment reflects the delays we experienced in launching our new products, the timing of submissions to the FDA for marketing clearance and the recognition that the hospital product approval process will need to be managed differently than originally anticipated.”  

Financial Results

Revenue for the three months ended December 31, 2009 was $26.3 million, including $1.0 million from new products, compared with $24.6 million for the three months ended December 31, 2008.  The increase in revenue for the fourth quarter of 2009 compared with the same period of 2008 was primarily driven by the $3.3 million in revenue realized from an agreement to license certain of the Company’s tissue processing technology.  This increase in revenue was partially offset by the anticipated reduction in revenue from the client services business and a decline in domestic unit sales volume.  Excluding client services, private label demineralized bone matrix and the license agreement revenue, fourth quarter 2009 revenue declined 3% compared with fourth quarter 2008 revenue.  

Revenue for the full year ended December 31, 2009 was $96.7 million compared with $103.8 million reported for 2008.  New product revenue was $1.3 million for 2009.  The decline in revenue for the year was primarily driven by: the anticipated reduction in revenue from the Company’s services businesses, which declined $6.4 million; a decline in international revenue reflecting the challenging general economic conditions and the impact from the temporary suspension of tissue products from the Company’s Bulgarian subsidiary instituted in December 2008 and removed in late July 2009; and lower domestic unit sales volume.  This decline was partially offset by the revenue received in conjunction with the Company’s aforementioned license agreement.

Net income for the fourth quarter ended December 31, 2009 was $890,000, or $0.05 per diluted share, compared with net loss of $409,000, or $0.02 per share, for the fourth quarter of 2008.  Net loss for the full year ended December 31, 2009 was $4.0 million, or $0.22 per share, compared with net income of $2.2 million, or $0.12 per diluted share, for 2008.  The net loss in 2009 is primarily due to the Company’s anticipated reductions in service revenue and the resulting lower gross margins.  Net loss for 2009 was partially offset by the $2.3 million in profit that the Company’s agreement to license certain tissue processing technology contributed to net income.


Based upon current market conditions, the exit of certain lines of business in 2009, the realization of all of revenue under the licensing arrangements in 2009, the regulatory environment and the Company’s internal expectations, Osteotech is providing the following financial guidance for 2010:

  • Total revenue is expected to range between $97 million and $101 million, with between $10 million and $12 million in revenue stemming from new products; and
  • Net income is expected to range between breakeven and a loss of $.05 per share.  

Conference Call Today, March 4, 2010

The Osteotech management team will host a conference call on March 4, 2010 at 9:00 a.m. (EST) to discuss fourth quarter and full year 2009 financial results, recent corporate developments and guidance for 2010.  The call can be accessed by dialing 1-866-202-4367 (domestic) or 1-617-213-8845 (international) and indicating access code 56692568.  The conference call will also be simultaneously webcast at  A replay of the call will be available two hours after completion of the live call through midnight, Thursday, March 18, 2010 by dialing 1-888-286-8010 and indicating access code 47904889.

About Osteotech

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing biologic solutions for regenerative medicine to support surgeons and their patients in the repair of the musculoskeletal system through the development of innovative therapy-driven products that alleviate pain, promote biologic healing and restore function.  For further information regarding Osteotech or the conference call, please go to Osteotech’s website at

Certain statements made throughout this press release that are not historical facts are forward-looking statements (as defined in the Private Securities Litigation Reform Act of 1995) regarding the Company’s future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company’s ability to develop and introduce new products, differences in anticipated and actual product and service introduction dates, the ultimate success of those products in the marketplace, the continued acceptance and growth of current products and services, the impact of competitive products and services, the availability of sufficient quantities of suitable donated tissue and the success of cost control and margin improvement efforts. For a more detailed discussion of certain of these factors, see the Company’s periodic reports filed with the Securities and Exchange Commission from time to time, including the latest Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All information in this press release is as of March 4, 2010 and the Company does not intend to update this information.

                         OSTEOTECH, INC. and Subsidiaries                     
                       CONSOLIDATED STATEMENTS OF OPERATIONS                  
                   (dollars in thousands, except per share data)              
                                  Three Months Ending          Year Ending    
                                       December 31,            December 31,   
                                  -------------------        ---------------- 
                                     2009        2008        2009        2008 
                                     ----        ----        ----        ---- 
    Revenue                       $26,315     $24,567     $96,678    $103,814 
    Cost of revenue                12,702      11,148      49,108      48,770 
                                   ------      ------      ------      ------ 
    Gross profit                   13,613      13,419      47,570      55,044 
    Marketing, selling and                                                    
     general and administrative 
     expenses                      10,962      11,553      43,996      45,032 
    Research and development                                                  
     expenses                       1,291       2,162       6,486       7,435 
                                    -----       -----       -----       ----- 
                                   12,253      13,715      50,482      52,467 
    Operating income (loss)         1,360        (296)     (2,912)      2,577 
    Interest expense, net            (349)       (310)     (1,412)     (1,072)
    Other                             (64)          8          42         961 
                                      ---          --          --         --- 
    Income (loss) before income 
     taxes                            947        (598)     (4,282)      2,466 
    Income tax expense (benefit)       57        (189)       (265)        263 
                                       --        ----        ----         --- 
    Net income (loss)                $890       $(409)    $(4,017)     $2,203 
                                     ====       =====     =======      ====== 
    Earnings (loss) per share:                                                
      Basic                         $0.05      $(0.02)     $(0.22)      $0.12 
      Diluted                       $0.05      $(0.02)     $(0.22)      $0.12 
    Shares used in computing 
     earnings (loss) per share:                       
      Basic                    18,028,682  17,918,606  17,968,971  17,833,902 
      Diluted                  18,163,717  17,918,606  17,968,971  18,083,584 
                           CONSOLIDATED SEGMENT REVENUE DETAIL        
                                  (dollars in thousands)              
                                          Three Months Ended     Year Ended 
                                             December 31,        December 31,
                                             ------------       -------------
                                             2009    2008       2009     2008
                                             ----    ----       ----     ----
    DBM                                   $13,337 $14,398    $56,782  $61,961
    Hybrid/Synthetic                        1,286     900      3,575    3,087
    Traditional Tissue                      5,713   4,651     21,534   20,258
    Spinal Allografts                       1,918   2,020      7,626    8,499
    Client Services                           130   1,674      2,143    8,201
    Other Product Lines                     3,931     924      5,018    1,808
                                            -----     ---      -----    -----
    Revenue                               $26,315 $24,567    $96,678 $103,814
                                          ======= =======    ======= ========
                              OSTEOTECH, INC. and Subsidiaries              
                            CONDENSED CONSOLIDATED BALANCE SHEETS           
                                   (dollars in thousands)                 
                                                     December 31, December 31,
                                                            2009         2008
                                                            ----         ----
    Cash and cash equivalents                            $10,708      $18,823
    Accounts receivable, net                              16,165       17,968
    Deferred processing costs                             38,562       38,715
    Inventories                                            1,819        1,467
    Prepaid expenses and other current assets              3,247        3,115
                                                           -----        -----
        Total current assets                              70,501       80,088
    Property, plant and equipment, net                    29,575       34,005
    Other assets                                          16,861       13,022
                                                          ------       ------
                                                        $116,937     $127,115
                                                        ========     ========
        Liabilities and Stockholders' Equity                             
    Accounts payable and accrued liabilities             $16,206      $23,569
    Current maturities of capital lease                                  
     obligation                                              994          895
                                                             ---          ---
        Total current liabilities                         17,200       24,464
    Capital lease obligation                              12,181       13,175
    Other liabilities                                      7,270        6,626
                                                           -----        -----
        Total liabilities                                 36,651       44,265
    Stockholders' equity                                  80,286       82,850
                                                          ------       ------
                                                        $116,937     $127,115
                                                        ========     ========

SOURCE Osteotech, Inc.

Back to top



SOURCE Osteotech, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix
2. Osteotech Completes Enrollment for DuraTech(TM) BioRegeneration Matrix Clinical Trial
3. Osteotechs MagniFuse(TM) Technology Used in First U.S. Surgery
4. Osteotech Reports Third Quarter 2009 Financial Results
5. Osteotech Highlights Three Procedure-Specific MagniFuse(TM) Bone Grafting Products at the NASS 2009 Annual Meeting
6. Osteotech Announces Preliminary Fourth Quarter 2009 Revenue
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. Spherix Reports Second Quarter Earnings
9. Tapestry Reports Second Quarter 2007 Results
10. Callisto Reports on Second-Quarter 2007 Milestones
11. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
Post Your Comments:
(Date:11/26/2015)... Bajos, November 26, 2015 Un ... de Bremachlorin para el cáncer avanzado.   ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Cancer Research . --> Clinical Cancer Research ...
(Date:11/26/2015)... , November 26, 2015 --> ... to use SyMRI to find optimal contrast weighting of MRI ... metastases, and has signed a research agreement with SyntheticMR in ... hospital. Using SyMRI, it is possible to generate multiple contrast ... after the patient has left, thus making it possible to ...
(Date:11/26/2015)... November 26, 2015 ... the "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Country Segment Forecasts, ... their offering. --> ) ... "2016 Future Horizons and Growth Strategies in ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors has released ... Surviving Mesothelioma has just posted the findings on the website. Click here to ... cases of 136 mesothelioma patients who were treated with chemotherapy followed by EPP surgery. ...
(Date:11/27/2015)... ... 27, 2015 , ... The print component of “Supporting Our ... Dallas, New York, Minneapolis, South Florida, with a circulation of approximately 250,000 copies ... a vast social media strategy and across a network of top news sites ...
(Date:11/27/2015)... DE (PRWEB) , ... November 27, 2015 , ... ... member of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s ... an independent group of Microsoft Dynamics SL software users, partners, industry experts and ...
(Date:11/27/2015)... , ... November 27, 2015 , ... CBD College ... of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. ... accredited colleges, as only one of twelve colleges and universities in the state of ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer and distributor ... Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. , ... up-to-date with a version of Asterisk that will receive not only security fixes, ...
Breaking Medicine News(10 mins):